– Phase 2 trial of adults with Osteogenesis Imperfecta (OI) is enrolling patients in the US and EU WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the dosing of the first patient in […]

(NASDAQ:IRTC), SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook

(NASDAQ:AGMH),(NasdaqGM:AMBR), NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (NASDAQ: AGMH), is one of the few publicly-listed companies at US market with both Crypto ASIC chip design (“ASIC”) and High-performance computing server production, signed a Memorandum of Understanding (MOU) with Amber Premium (NASDAQ: AMBR), a globally leading digital wealth management platform,

(NASDAQ:RARE), Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Jan. 12,

(NASDAQ:MASK), HONG KONG, Jan. 12, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider with the inspiration to become a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced that its wholly-owned Finnish subsidiary, Aurora Core Technology

(TASE:BWAY.TA),(NasdaqGM:BWAY), BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief's Proliv(TM)Rx system, a Class III device, as an

— Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 — — Enrolling Phase 2 REKINDLE Trial of RE104 in Adjustment Disorder (AjD); Initial Data Expected in 1Q 2027 —— On Track to Initiate Phase 2 RECLAIM Trial

(TSX:NVA), ISS cites flexibility for NuVista Shareholders to realize certain cash value or continued participation in endorsing the Arrangement Your vote is important – Vote well in advance of the proxy voting deadline on Wednesday, January 21, 2026 at 8:00 a.m. (Calgary Time) NuVista Shareholders are encouraged to make an election with respect to their

(NASDAQ:URBN), PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) — Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands including the Anthropologie, Free People, FP Movement, Urban Outfitters and Nuuly brands, today announced net sales for the two and eleven months ended December 31, 2025. Total Company

(NYSE:FCN), WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the expansion of its transactions, shareholder activism and issues management capabilities with the appointments of Dan Scorpio and Heather Wilson as Senior Managing Directors within the firm's Strategic Communications segment. “Guiding a transaction from announcement through close has never been